Connect with us

Life Sciences

Gene editing startup Pairwise adds 3 execs in preparing for first food launch

Gearing up for a new gene editing-boosted salad, foodtech startup Pairwise has added three executives to its management team.
The post Gene editing startup…

Published

on

This article was originally published by WRAL Techwire

DURHAM – Gearing up for a new gene editing-boosted salad, foodtech startup Pairwise has added three executives to its management team.

As Conscous – what the company calls a “nutrient-dense leafy green mix” – Pairwise says the three vice presidents will “fill out” its Commercial Leadership Team.

They are:

  • Megan Thomas, Vice President for Marketing & Communications
  • Neil Merritt, Vice President of Sales
  • John Schouten, Vice President of Supply Chain

“Their combined ten decades of experience across key areas will transform our vision on how to bring great products to market,” said Haven Baker, co-founder and Chief Business Officer at Pairwise.

Pairwise has drawn more than $200 million in investment capital and also has a multi-year collaboration agreement with Bayer Crop Science valued at $100 million.

It has more than 150 employees and expects to add more this year, the company said.

Durham biotech fertilizes gene-editing creation of new fruit and veggie varieties with $90M funding

The post Gene editing startup Pairwise adds 3 execs in preparing for first food launch first appeared on WRAL TechWire.

gene editing

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending